SkinBioTherapeutics (LON:SBTX) Stock Price Up 9.8% – Here’s What Happened

SkinBioTherapeutics plc (LON:SBTX) shares shot up 9.8% during mid-day trading on Thursday . The company traded as high as GBX 10.50 and last traded at GBX 10.50. 555,156 shares traded hands during mid-day trading, a decline of 90% from the average session volume of 5,624,534 shares. The stock had previously closed at GBX 9.56.

SkinBioTherapeutics Stock Up 14.2%

The company has a debt-to-equity ratio of 10.55, a current ratio of 4.84 and a quick ratio of 10.01. The business’s 50 day simple moving average is GBX 15.64 and its 200 day simple moving average is GBX 15.34. The company has a market capitalization of £28.27 million, a PE ratio of -35.22 and a beta of 0.73.

SkinBioTherapeutics (LON:SBTX) last posted its quarterly earnings results on Monday, December 8th. The company reported GBX (0.31) earnings per share for the quarter. SkinBioTherapeutics had a negative net margin of 15.01% and a negative return on equity of 10.01%.

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.